ArticleThoracic cancer2022
Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer.
Yutaka Takahara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled ittrialcites it